Gecilmara Salviato

Prof. Dr. Gecilmara Salviato

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2020 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
ENEdgard Torres dos Reis Neto
Edgard Torres dos Reis Neto
AKAdriana Maria Kakehasi
Adriana Maria Kakehasi
MPMarcelo M Pinheiro
Marcelo M Pinheiro
GFGilda Aparecida Ferreira
Gilda Aparecida Ferreira
CMCláudia Diniz Lopes Marques
Cláudia Diniz Lopes Marques
JPJosé Roberto Provenza
José Roberto Provenza
Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.

1 May 2015 in Autoimmunity Reviews
Verified
Journal Article
Closed access
BCBernardo M. Cunha
Bernardo M. Cunha
LMLicia Maria H. Mota
Licia Maria H. Mota
GSGecilmara Salviato
Gecilmara Salviato
ISIzabella P. Safe
Izabella P. Safe
MLMarcus Vinícius Guimarães de Lacerda
Marcus Vinícius Guimarães de Lacerda

8 March 2016 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
IGIngrid Herta Rotstein Grein
Ingrid Herta Rotstein Grein
NGNoortje Groot
Noortje Groot
MLMarcela Ignacchiti Lacerda
Marcela Ignacchiti Lacerda
NWNico Wulffraat
Nico Wulffraat
GSGecilmara Salviato
Gecilmara Salviato
Patients with Systemic Lupus Erythematosus (SLE) are at increased risk for infections. Vaccination is a powerful tool to prevent infections, even in immunocompromised patients. Most non-live vaccines are immunogenic and safe in patients with SLE, even if antibody titres are frequently lower than those of healthy controls. Human papillomavirus (HPV) infections are more prevalent in SLE patients when compared to the healthy population. Low-risk types of this virus cause anogenital warts, while high risk types are strongly related to pre-malignant cervical abnormalities and cervical cancer. HPV vaccines have been developed to prevent these conditions. Although little is known about HPV vaccination in SLE, few studies in patients with autoimmune rheumatic diseases (AIRDs) have shown that HPV vaccines are safe, and capable to induce an immunogenic response in this group of patients. To date, available data suggest that HPV vaccines can be given safely to SLE patients. Given the increased incidence of cervical abnormalities due to HPV in SLE patients, this vaccination should be encouraged.

29 April 2019 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
GSGecilmara Salviato
Gecilmara Salviato
LMLicia Maria Henrique Da Mota
Licia Maria Henrique Da Mota
AKAdriana Maria Kakehasi
Adriana Maria Kakehasi
ASAlexander Wagner Silva De Souza
Alexander Wagner Silva De Souza
ARAline Rocha
Aline Rocha
VTVirginia Fernandes Moça Trevisani
Virginia Fernandes Moça Trevisani
In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the safety of YFV in patients with CIMID, considering the immunosuppression degree conferred by the treatment used. It was not possible to establish recommendations on the effectiveness of YFV in these patients as there is no consistent evidence to support these recommendations. This paper approaches a real need, assessed by clinicians and patient care groups, to address specific questions on the management of YFV in patients with CIMID living or traveling to YF endemic areas, involving specialists from many areas together with patients, and might have global applicability, contributing to and supporting vaccination practices. We recommended a shared decision-making approach on taking or not the YFV.

28 July 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SCSelma Regina Penha Silva Cerqueira
Selma Regina Penha Silva Cerqueira
PDPatrícia Duarte Deps
Patrícia Duarte Deps
DCDébora Vilela Cunha
Débora Vilela Cunha
NBNatanael Victor Furtunato Bezerra
Natanael Victor Furtunato Bezerra
DBDaniel Holanda Barroso
Daniel Holanda Barroso
Ciro Martins GomesCiro Martins Gomes
Ciro Martins Gomes
Protective effects of Bacillus Calmette–Guérin (BCG) vaccination and clofazimine and dapsone treatment against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported. Patients at risk for leprosy represent an interesting model for assessing the effects of these therapies on the occurrence and severity of coronavirus disease 2019 (COVID-19). We assessed the influence of leprosy-related variables in the occurrence and severity of COVID-19. We performed a 14-month prospective real-world cohort study in which the main risk factor was 2 previous vaccinations with BCG and the main outcome was COVID-19 detection by reverse transcription polymerase chain reaction (RT-PCR). A Cox proportional hazards model was used. Among the 406 included patients, 113 were diagnosed with leprosy. During follow-up, 69 (16.99%) patients contracted COVID-19. Survival analysis showed that leprosy was associated with COVID-19 (p<0.001), but multivariate analysis showed that only COVID-19-positive household contacts (hazard ratio (HR) = 8.04; 95% CI = 4.93–13.11) and diabetes mellitus (HR = 2.06; 95% CI = 1.04–4.06) were significant risk factors for COVID-19. Leprosy patients are vulnerable to COVID-19 because they have more frequent contact with SARS-CoV-2-infected patients, possibly due to social and economic limitations. Our model showed that the use of corticosteroids, thalidomide, pentoxifylline, clofazimine, or dapsone or BCG vaccination did not affect the occurrence or severity of COVID-19. Leprosy is a chronic infectious disease caused by Mycobacterium leprae and Mycobacterium lepromatosis. Coronavirus disease 2019 (COVID-19) results in an intense inflammatory response that is dependent on several immune mediators. Since the beginning of the COVID-19 pandemic, an interaction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and M. leprae infection has been considered a possibility. Protective effects of Bacillus Calmette–Guérin (BCG) vaccination and clofazimine and dapsone treatment against SARS-CoV-2 infection have been reported. Patients at risk for leprosy represent an interesting model for assessing the effects of these therapies on the occurrence and severity of COVID-19. We assessed the influence of leprosy-related variables in the occurrence and severity of COVID-19. We performed a 14-month study. Among the 406 included patients, 113 were diagnosed with leprosy. During follow-up, 69 (16.99%) patients contracted COVID-19. Our analysis showed that only COVID-19-positive household contacts and diabetes mellitus were significant risk factors for COVID-19. Leprosy patients are vulnerable to COVID-19 because they have more frequent contact with SARS-CoV-2-infected patients, possibly due to social and economic limitations. Our model showed that the use of clofazimine or dapsone or BCG vaccination did not affect the occurrence or severity of COVID-19.

15 December 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
CMClaudia Marques
Claudia Marques
AKAdriana Maria Kakehasi
Adriana Maria Kakehasi
AGAna Paula Monteiro Gomides
Ana Paula Monteiro Gomides
EPEduardo Dos Santos Paiva
Eduardo Dos Santos Paiva
EREdgard Torres dos Reis-Neto
Edgard Torres dos Reis-Neto
MPMarcelo M Pinheiro
Marcelo M Pinheiro
Background: Patients with immune-mediated rheumatic diseases (IMRD) are at increased risk of infections, including significant morbidity and high mortality. Considering the potential for unfavorable outcomes of SARS-CoV-2 infection in patients with IMRD, several questions were raised regarding the impact of COVID-19 at the start of the pandemic. Objective: This paper presents the protocol of a study that aims to prospectively evaluate patients with IMRD and a confirmed COVID-19 diagnosis (using criteria provided by the Brazilian Ministry of Health). Methods: The study comprised a prospective, observational cohort (patients with IMRD and COVID-19) and a comparison group (patients with only IMRD), with a follow-up time of 6 months to evaluate differences in health outcomes. The primary outcomes will be changes in IMRD disease activity after SARS-CoV-2 infection at 4 time points: (1) at baseline, (2) within 4-6 weeks after infection, (3) at 3 months after the second assessment (±15 days), and (4) at 6 months (±15 days). The secondary outcomes will be the progression rate to moderate or severe forms of COVID-19, need for intensive care unit admission and mechanical ventilation, death, and therapeutic changes related to IMRD. Two outcomes—pulmonary and thromboembolic events in patients with both IMRD and SARS-CoV-2 infection—are of particular interest and will be monitored with close attention (clinical, laboratory, and function tests as well as imaging). Results: Recruitment opened in May 2020, with 1300 participants recruited from 43 sites as of November 2020. Patient recruitment will conclude by the end of December 2020, with follow-up occurring until April 2021. Data analysis is scheduled to start after all inclusion data have been collected, with an aim to publish a peer-reviewed paper in December 2020. Conclusions: We believe this study will provide clinically relevant data on the general impact of COVID-19 on patients with IMRD. Trial Registration: Brazilian Registry of Clinical Trials RBR-33YTQC; http://www.ensaiosclinicos.gov.br/rg/RBR-33ytqc/ International Registered Report Identifier (IRRID): DERR1-10.2196/24357